Brokerages Set Enhabit, Inc. (NYSE:EHAB) PT at $8.75

Enhabit, Inc. (NYSE:EHAB - Get Free Report) has received a consensus recommendation of "Hold" from the six research firms that are currently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, four have issued a hold rating and one has given a buy rating to the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $8.75.

Several research firms have recently commented on EHAB. Leerink Partners reaffirmed a "market perform" rating and set a $8.00 target price (down from $8.50) on shares of Enhabit in a report on Tuesday, November 19th. Jefferies Financial Group raised Enhabit from a "hold" rating to a "buy" rating and upped their target price for the company from $8.25 to $9.50 in a report on Monday, December 9th.

Insider Buying and Selling at Enhabit

In other Enhabit news, Director Stuart M. Mcguigan bought 15,000 shares of the firm's stock in a transaction dated Tuesday, December 10th. The stock was acquired at an average price of $8.81 per share, with a total value of $132,150.00. Following the completion of the transaction, the director now directly owns 46,810 shares in the company, valued at approximately $412,396.10. This represents a 47.15 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Jeffrey Bolton bought 4,000 shares of the stock in a transaction on Thursday, December 12th. The shares were acquired at an average cost of $8.69 per share, for a total transaction of $34,760.00. Following the purchase, the director now owns 98,144 shares in the company, valued at approximately $852,871.36. This represents a 4.25 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 1.90% of the stock is currently owned by corporate insiders.

Remove Ads

Hedge Funds Weigh In On Enhabit

Several institutional investors have recently bought and sold shares of EHAB. Deerfield Management Company L.P. Series C grew its holdings in Enhabit by 0.3% during the fourth quarter. Deerfield Management Company L.P. Series C now owns 5,010,972 shares of the company's stock valued at $39,136,000 after purchasing an additional 13,226 shares during the last quarter. 8 Knots Management LLC boosted its holdings in Enhabit by 16.4% during the fourth quarter. 8 Knots Management LLC now owns 4,430,898 shares of the company's stock valued at $34,605,000 after acquiring an additional 623,602 shares during the period. AREX Capital Management LP grew its position in shares of Enhabit by 2.0% in the fourth quarter. AREX Capital Management LP now owns 2,490,795 shares of the company's stock valued at $19,453,000 after purchasing an additional 48,874 shares during the last quarter. Systematic Financial Management LP increased its stake in shares of Enhabit by 8.6% in the fourth quarter. Systematic Financial Management LP now owns 1,996,113 shares of the company's stock worth $15,590,000 after purchasing an additional 157,914 shares during the period. Finally, Dimensional Fund Advisors LP lifted its position in shares of Enhabit by 12.3% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,953,941 shares of the company's stock worth $15,260,000 after purchasing an additional 213,774 shares during the last quarter.

Enhabit Stock Up 1.1 %

NYSE EHAB traded up $0.09 on Thursday, hitting $8.37. 482,054 shares of the stock traded hands, compared to its average volume of 266,522. The stock has a 50-day moving average of $8.13 and a 200 day moving average of $7.90. Enhabit has a twelve month low of $6.85 and a twelve month high of $11.74. The company has a market capitalization of $420.88 million, a P/E ratio of -3.61 and a beta of 1.83. The company has a current ratio of 1.46, a quick ratio of 1.46 and a debt-to-equity ratio of 0.85.

About Enhabit

Enhabit, Inc provides home health and hospice services in the United States. Its home health services include patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care and chronic pain, along with disease-specific plans for patients with diabetes, congestive heart failure, post-orthopedic surgery, or injury and respiratory diseases; and physical, occupational and speech therapists provide therapy services.